ADV |
News
- BlueLinx Announces CEO Succession
04/21/2021 / 22:30 - GlobeNewswire - Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
04/21/2021 / 13:30 - GlobeNewswire - BlueLinx to Host First Quarter 2021 Results Conference Call and Webcast
04/20/2021 / 22:30 - GlobeNewswire - Cyclerion Therapeutics to Host Pipeline Update Webinar
04/20/2021 / 13:00 - GlobeNewswire - Advantage Solutions Announces First Quarter 2021 Earnings Release Date and Conference Call
04/19/2021 / 14:00 - GlobeNewswire - Clark Capital Welcomes Jim Warren as Chief Operating Officer
04/06/2021 / 14:00 - GlobeNewswire - Makara Opens Waitlist for First Ever SEC Registered Crypto Robo-Advisor
03/30/2021 / 15:00 - GlobeNewswire - Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide
03/30/2021 / 13:57 - GlobeNewswire - Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
03/30/2021 / 07:21 - GlobeNewswire - Trinity Alps Private Investment Business Marks 1st Anniversary with $450M+ AUM
03/24/2021 / 20:04 - GlobeNewswire - Cyclerion Therapeutics Announces Departure of Chief Medical Officer
03/18/2021 / 22:00 - GlobeNewswire - Advantage Solutions to Participate at Jefferies Virtual Business Services Summit
03/18/2021 / 21:05 - GlobeNewswire - Advantage Solutions Reports Fourth Quarter and Full Fiscal Year 2020 Financial Results Above Prior Outlook and Raises 2021 Adjusted EBITDA Expectation
03/16/2021 / 21:05 - GlobeNewswire - Fulcrum Partners Reports on Executive Benefits Post 2020
03/16/2021 / 15:00 - GlobeNewswire - Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide
03/16/2021 / 13:32 - GlobeNewswire